You are here » Home » Markets » Stocks » Announcements

ANNOUNCEMENTS

Announcement for "Aurobindo Pharma Ltd"

Aurobindo Pharma Ltd Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011

  • 05/12/2016
  • |
  • bse

Aurobindo Pharma Ltd Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011

  • 05/12/2016
  • |
  • bse

Aurobindo Pharma Ltd Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011

  • 05/12/2016
  • |
  • bse

Aurobindo Pharma Ltd Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011

  • 30/11/2016
  • |
  • bse

Aurobindo Pharma Ltd Arrow Generiques to acquire select assets in France from Teva

  • 25/11/2016
  • |
  • bse

Aurobindo Pharma Ltd Transcript of earnings call

  • 23/11/2016
  • |
  • bse

Aurobindo Pharma Ltd Aurobindo Pharma Ltd reply to clarification sought by the exchange

  • 23/11/2016
  • |
  • bse

Aurobindo Pharma Ltd Clarification sought from Aurobindo Pharma Ltd

  • 22/11/2016
  • |
  • bse

Aurobindo Pharma Ltd Presentation to the Investors / Analysts

  • 15/11/2016
  • |
  • bse

Aurobindo Pharma Ltd Fixes Record Date for Interim Dividend

  • 15/11/2016
  • |
  • bse

Aurobindo Pharma Ltd Results Press Release for September 30 2016

  • 14/11/2016
  • |
  • bse

Aurobindo Pharma Ltd Investors Presentation

  • 14/11/2016
  • |
  • bse

Aurobindo Pharma Ltd Board declares Interim Dividend

  • 14/11/2016
  • |
  • bse

Aurobindo Pharma Ltd Announces Q2 results (Standalone & Consolidated) & Limited Review Report (Standalone & Consolidated)

  • 14/11/2016
  • |
  • bse

Aurobindo Pharma Ltd Analyst / Investor Call

  • 07/11/2016
  • |
  • bse

Aurobindo Pharma Ltd Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011

  • 01/11/2016
  • |
  • bse

Aurobindo Pharma Ltd Closure of Trading Window

  • 29/10/2016
  • |
  • bse

Aurobindo Pharma Ltd Q2 results on Nov 14 2016

  • 29/10/2016
  • |
  • bse

Aurobindo Pharma Ltd Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations 2015 for Quarter ended S

  • 14/10/2016
  • |
  • bse

Aurobindo Pharma Ltd Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011

  • 07/10/2016
  • |
  • bse

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard